The 4 most recent market catalysts affecting $TNDM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair's initiation of coverage on Tandem Diabetes Care with an Outperform rating signals a positive outlook from a reputable financial institution. This event is significan…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26
RBC Capital's analyst Kendall Au maintained an 'Outperform' rating for Tandem Diabetes Care (TNDM), signaling continued confidence in the company's long-term prospects. However, th…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q2 EPS results and reaffirmed its FY2026 sales guidance.
This headline represents a significant corporate catalyst for Tandem Diabetes Care (TNDM). Exceeding EPS expectations and, crucially, reaffirming ambitious long-term sales guidance…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Mizuho analyst Anthony Petrone maintained a Neutral rating on Tandem Diabetes Care (TNDM) but lowered the price target from $24 to $20. This action signals a slightly less optimist…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.